For instance, treatments commonly used in SpA, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or tumor necrosis factor (TNF) inhibitors, may have variable effects or contraindications in patients with concurrent SLE due to the risk of lupus flares or drug-induced complications. The gene discussed is TNF; the disease is systemic lupus erythematosus.